Regeneron Pharmaceuticals, Inc. (0R2M.L)
USD 724.22
(-2.2%)
USD 724.22
(-2.2%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 2.81 Billion USD | 25.8% |
| 2022 | 5.61 Billion USD | 19.86% |
| 2021 | 4.68 Billion USD | 23.33% |
| 2020 | 3.8 Billion USD | -21.98% |
| 2019 | 4.87 Billion USD | 30.17% |
| 2018 | 3.74 Billion USD | 10.21% |
| 2017 | 3.39 Billion USD | 5.13% |
| 2016 | 3.22 Billion USD | 31.35% |
| 2015 | 2.45 Billion USD | 38.45% |
| 2014 | 1.77 Billion USD | 49.33% |
| 2013 | 1.18 Billion USD | 42.22% |
| 2012 | 836.3 Million USD | 29.31% |
| 2011 | 646.76 Million USD | 16.65% |
| 2010 | 554.45 Million USD | 22.75% |
| 2009 | 451.68 Million USD | 37.98% |
| 2008 | 327.36 Million USD | 36.7% |
| 2007 | 239.47 Million USD | 46.96% |
| 2006 | 162.95 Million USD | 340.4% |
| 2005 | -67.78 Million USD | -144.26% |
| 2004 | 153.15 Million USD | 1.56% |
| 2003 | 150.8 Million USD | 9.71% |
| 2002 | 137.45 Million USD | 35.9% |
| 2001 | 101.14 Million USD | 46.62% |
| 2000 | 68.98 Million USD | 26.12% |
| 1999 | 54.7 Million USD | 19.43% |
| 1998 | 45.8 Million USD | 20.53% |
| 1997 | 38 Million USD | -5.71% |
| 1996 | 40.3 Million USD | 15.14% |
| 1995 | 35 Million USD | -33.21% |
| 1994 | 52.4 Million USD | 6.07% |
| 1993 | 49.4 Million USD | 65.77% |
| 1992 | 29.8 Million USD | 626.83% |
| 1991 | 4.1 Million USD | 105.0% |
| 1990 | 2 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 1.85 Billion USD | 0.77% |
| 2024 Q1 | 1.83 Billion USD | -3.96% |
| 2024 Q3 | 1.98 Billion USD | 10.65% |
| 2023 Q3 | 1.71 Billion USD | -1.2% |
| 2023 FY | 7.06 Billion USD | 25.8% |
| 2023 Q2 | 1.73 Billion USD | 2.05% |
| 2023 Q1 | 1.7 Billion USD | 0.28% |
| 2023 Q4 | 1.91 Billion USD | 11.57% |
| 2022 Q4 | 1.69 Billion USD | 21.67% |
| 2022 Q2 | 1.25 Billion USD | -1.6% |
| 2022 Q1 | 1.27 Billion USD | -4.2% |
| 2022 Q3 | 1.39 Billion USD | 11.29% |
| 2022 FY | 5.61 Billion USD | 19.86% |
| 2021 Q1 | 1.1 Billion USD | 22.73% |
| 2021 Q3 | 1.15 Billion USD | 4.99% |
| 2021 Q4 | 1.32 Billion USD | 15.36% |
| 2021 FY | 4.68 Billion USD | 23.33% |
| 2021 Q2 | 1.09 Billion USD | -0.94% |
| 2020 Q3 | 966.9 Million USD | -5.22% |
| 2020 FY | 3.8 Billion USD | -21.98% |
| 2020 Q2 | 1.02 Billion USD | 12.0% |
| 2020 Q1 | 910.8 Million USD | -28.28% |
| 2020 Q4 | 902.8 Million USD | -6.63% |
| 2019 FY | 4.87 Billion USD | 30.17% |
| 2019 Q4 | 1.26 Billion USD | 17.23% |
| 2019 Q3 | 1.08 Billion USD | -26.08% |
| 2019 Q2 | 1.46 Billion USD | 39.24% |
| 2019 Q1 | 1.05 Billion USD | -3.65% |
| 2018 Q4 | 1.09 Billion USD | 17.95% |
| 2018 FY | 3.74 Billion USD | 10.21% |
| 2018 Q3 | 926.2 Million USD | 3.58% |
| 2018 Q2 | 894.17 Million USD | 7.82% |
| 2018 Q1 | 829.35 Million USD | -11.57% |
| 2017 Q1 | 804.28 Million USD | -0.11% |
| 2017 FY | 3.39 Billion USD | 5.13% |
| 2017 Q3 | 836.51 Million USD | 2.4% |
| 2017 Q4 | 937.89 Million USD | 12.12% |
| 2017 Q2 | 816.88 Million USD | 1.57% |
| 2016 Q4 | 805.14 Million USD | -0.98% |
| 2016 Q1 | 759.78 Million USD | 0.48% |
| 2016 Q2 | 851.96 Million USD | 12.13% |
| 2016 FY | 3.22 Billion USD | 31.35% |
| 2016 Q3 | 813.09 Million USD | -4.56% |
| 2015 Q3 | 635.91 Million USD | 12.57% |
| 2015 FY | 2.45 Billion USD | 38.45% |
| 2015 Q1 | 502.1 Million USD | 1.34% |
| 2015 Q2 | 564.91 Million USD | 12.51% |
| 2015 Q4 | 756.16 Million USD | 18.91% |
| 2014 Q4 | 495.48 Million USD | 1.64% |
| 2014 FY | 1.77 Billion USD | 49.33% |
| 2014 Q1 | 396.22 Million USD | 13.14% |
| 2014 Q2 | 396.91 Million USD | 0.17% |
| 2014 Q3 | 487.47 Million USD | 22.82% |
| 2013 Q4 | 350.22 Million USD | 8.88% |
| 2013 FY | 1.18 Billion USD | 42.22% |
| 2013 Q3 | 321.65 Million USD | 23.75% |
| 2013 Q2 | 259.92 Million USD | 0.92% |
| 2013 Q1 | 257.55 Million USD | 7.87% |
| 2012 FY | 836.3 Million USD | 29.31% |
| 2012 Q4 | 238.76 Million USD | 16.37% |
| 2012 Q1 | 197.29 Million USD | 19.29% |
| 2012 Q2 | 195.07 Million USD | -1.12% |
| 2012 Q3 | 205.17 Million USD | 5.18% |
| 2011 Q1 | 152.8 Million USD | 4.77% |
| 2011 Q4 | 165.39 Million USD | 2.83% |
| 2011 Q2 | 167.73 Million USD | 9.77% |
| 2011 FY | 646.76 Million USD | 16.65% |
| 2011 Q3 | 160.84 Million USD | -4.11% |
| 2010 Q2 | 139.2 Million USD | 5.88% |
| 2010 FY | 554.45 Million USD | 22.75% |
| 2010 Q3 | 137.7 Million USD | -1.08% |
| 2010 Q4 | 145.85 Million USD | 5.92% |
| 2010 Q1 | 131.47 Million USD | -3.2% |
| 2009 Q1 | 93.82 Million USD | 4.47% |
| 2009 Q2 | 105.86 Million USD | 12.84% |
| 2009 Q3 | 118.27 Million USD | 11.72% |
| 2009 Q4 | 135.82 Million USD | 14.84% |
| 2009 FY | 451.68 Million USD | 37.98% |
| 2008 FY | 327.36 Million USD | 36.7% |
| 2008 Q4 | 89.8 Million USD | 5.38% |
| 2008 Q3 | 85.22 Million USD | 6.47% |
| 2008 Q2 | 80.04 Million USD | 10.72% |
| 2008 Q1 | 72.29 Million USD | -5.21% |
| 2007 Q3 | 60.97 Million USD | 15.49% |
| 2007 Q4 | 76.26 Million USD | 25.07% |
| 2007 FY | 239.47 Million USD | 46.96% |
| 2007 Q2 | 52.79 Million USD | 6.8% |
| 2007 Q1 | 49.43 Million USD | 13.9% |
| 2006 Q4 | 43.4 Million USD | 6.31% |
| 2006 FY | 162.95 Million USD | 340.4% |
| 2006 Q3 | 40.82 Million USD | 0.32% |
| 2006 Q2 | 40.69 Million USD | 7.01% |
| 2006 Q1 | 38.03 Million USD | 118.64% |
| 2005 Q3 | 47.33 Million USD | 1.02% |
| 2005 FY | -67.78 Million USD | -144.26% |
| 2005 Q2 | 46.85 Million USD | 11.41% |
| 2005 Q1 | 42.05 Million USD | 6.09% |
| 2005 Q4 | -204.03 Million USD | -531.05% |
| 2004 Q1 | 35.97 Million USD | -4.09% |
| 2004 FY | 153.15 Million USD | 1.56% |
| 2004 Q4 | 39.64 Million USD | 7.11% |
| 2004 Q3 | 37.01 Million USD | -8.68% |
| 2004 Q2 | 40.53 Million USD | 12.68% |
| 2003 Q2 | 37.2 Million USD | -1.7% |
| 2003 Q4 | 37.5 Million USD | -1.95% |
| 2003 FY | 150.8 Million USD | 9.71% |
| 2003 Q3 | 38.25 Million USD | 2.81% |
| 2003 Q1 | 37.84 Million USD | 0.08% |
| 2002 Q2 | 33.65 Million USD | 16.56% |
| 2002 Q1 | 28.87 Million USD | -12.05% |
| 2002 Q3 | 37.1 Million USD | 10.24% |
| 2002 Q4 | 37.82 Million USD | 1.93% |
| 2002 FY | 137.45 Million USD | 35.9% |
| 2001 Q3 | 27.5 Million USD | 25.12% |
| 2001 FY | 101.14 Million USD | 46.62% |
| 2001 Q1 | 18.83 Million USD | -6.7% |
| 2001 Q2 | 21.97 Million USD | 16.69% |
| 2001 Q4 | 32.83 Million USD | 19.39% |
| 2000 Q3 | 16.97 Million USD | -1.11% |
| 2000 Q2 | 17.16 Million USD | 7.78% |
| 2000 FY | 68.98 Million USD | 26.12% |
| 2000 Q1 | 15.92 Million USD | 27.42% |
| 2000 Q4 | 20.18 Million USD | 18.92% |
| 1999 Q1 | 13.5 Million USD | 12.5% |
| 1999 FY | 54.7 Million USD | 19.43% |
| 1999 Q4 | 12.5 Million USD | -18.83% |
| 1999 Q3 | 15.4 Million USD | 17.56% |
| 1999 Q2 | 13.1 Million USD | -2.96% |
| 1998 FY | 45.8 Million USD | 20.53% |
| 1998 Q3 | 11.9 Million USD | 2.59% |
| 1998 Q4 | 12 Million USD | 0.84% |
| 1998 Q1 | 10.5 Million USD | 12.9% |
| 1998 Q2 | 11.6 Million USD | 10.48% |
| 1997 Q3 | 9.2 Million USD | -6.12% |
| 1997 Q1 | 9.8 Million USD | -1.01% |
| 1997 FY | 38 Million USD | -5.71% |
| 1997 Q4 | 9.3 Million USD | 1.09% |
| 1997 Q2 | 9.8 Million USD | 0.0% |
| 1996 Q2 | 9.9 Million USD | 0.0% |
| 1996 Q4 | 9.9 Million USD | -6.6% |
| 1996 Q1 | 9.9 Million USD | 16.47% |
| 1996 FY | 40.3 Million USD | 15.14% |
| 1996 Q3 | 10.6 Million USD | 7.07% |
| 1995 FY | 35 Million USD | -33.21% |
| 1995 Q4 | 8.5 Million USD | -1.16% |
| 1995 Q3 | 8.6 Million USD | -3.37% |
| 1995 Q2 | 8.9 Million USD | -1.11% |
| 1995 Q1 | 9 Million USD | -29.69% |
| 1994 Q2 | 13.6 Million USD | 1.49% |
| 1994 Q4 | 12.8 Million USD | 1.59% |
| 1994 FY | 52.4 Million USD | 6.07% |
| 1994 Q3 | 12.6 Million USD | -7.35% |
| 1994 Q1 | 13.4 Million USD | -68.54% |
| 1993 Q2 | 11.1 Million USD | -1.77% |
| 1993 Q4 | 42.6 Million USD | 1752.17% |
| 1993 Q3 | 2.3 Million USD | -79.28% |
| 1993 FY | 49.4 Million USD | 65.77% |
| 1993 Q1 | 11.3 Million USD | 34.52% |
| 1992 Q3 | 8 Million USD | 19.4% |
| 1992 Q1 | 6.7 Million USD | 857.14% |
| 1992 FY | 29.8 Million USD | 626.83% |
| 1992 Q4 | 8.4 Million USD | 5.0% |
| 1992 Q2 | 6.7 Million USD | 0.0% |
| 1991 Q1 | - USD | 100.0% |
| 1991 Q3 | 2 Million USD | 150.0% |
| 1991 Q4 | 700 Thousand USD | -65.0% |
| 1991 FY | 4.1 Million USD | 105.0% |
| 1991 Q2 | 800 Thousand USD | 0.0% |
| 1990 Q1 | - USD | 0.0% |
| 1990 FY | 2 Million USD | 0.0% |
| 1990 Q4 | -8.3 Million USD | 0.0% |
| 1990 Q3 | - USD | 0.0% |
| 1990 Q2 | - USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | -61.217% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -23088.37% |
| Myriad Genetics, Inc. | 600.1 Million USD | -369.138% |
| Evolus, Inc. | 189.75 Million USD | -1383.619% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | -261.127% |
| Agilent Technologies, Inc. | 2.11 Billion USD | -33.111% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | -588.664% |
| uniQure N.V. | 285.08 Million USD | -887.527% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -4949.322% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -921.172% |
| bluebird bio, Inc. | 240.23 Million USD | -1071.909% |
| Abeona Therapeutics Inc. | 48.5 Million USD | -5704.503% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | -56.4% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -663.757% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | -558.317% |
| Dynavax Technologies Corporation | 219.14 Million USD | -1184.675% |
| Editas Medicine, Inc. | 247.3 Million USD | -1038.396% |
| FibroGen, Inc. | 398.11 Million USD | -607.161% |
| Geron Corporation | 70.44 Million USD | -3896.678% |
| Blueprint Medicines Corporation | 722.86 Million USD | -289.466% |
| IQVIA Holdings Inc. | 2.05 Billion USD | -37.131% |
| Illumina, Inc. | 3.81 Billion USD | 26.166% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | -524.245% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -7090.509% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | -76.342% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -1876.162% |
| Adicet Bio, Inc. | 152.03 Million USD | -1751.708% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | -106.883% |
| Insmed Incorporated | 949.26 Million USD | -196.578% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | -410.419% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | -158.429% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -6202.863% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | -432.182% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 93.066% |
| Waters Corporation | 943.51 Million USD | -198.384% |
| Zoetis Inc. | 2.76 Billion USD | -1.819% |
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 72.544% |
| Biogen Inc. | 5.2 Billion USD | 45.911% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -1131.109% |
| Nektar Therapeutics | 190.9 Million USD | -1374.728% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -2692.208% |
| Perrigo Company plc | 1.52 Billion USD | -84.187% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | -491.003% |
| Heron Therapeutics, Inc. | 120.65 Million USD | -2233.308% |
| Verastem, Inc. | 92.08 Million USD | -2957.317% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 41.041% |
| Imunon, Inc. | 21.03 Million USD | -13286.792% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -20139.918% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | -935.429% |
| Homology Medicines, Inc. | 9.87 Million USD | -28409.367% |
| OPKO Health, Inc. | 574.68 Million USD | -389.885% |
| Exelixis, Inc. | 1.58 Billion USD | -77.423% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -840.572% |
| TG Therapeutics, Inc. | 198.47 Million USD | -1318.466% |
| Incyte Corporation | 1.19 Billion USD | -136.481% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | -169.665% |